Medical News

RSS

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

Alcon reports 2009 fourth quarter results

Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.

11 Feb 2010

Chemical compound found in blood shows promise in preventing intractable form of heart failure

A chemical compound found normally in the blood has shown promise in treating and preventing an intractable form of heart failure in a mouse model of the disease, report researchers at the University of Illinois at Chicago College of Medicine.

11 Feb 2010

APCapital announces net income of $9.7M for fourth-quarter of 2009

American Physicians Capital, Inc. (APCapital) today announced net income of $9.7 million or $.94 per diluted common share for the fourth quarter of 2009. For the year ended December 31, 2009, APCapital generated net income of $40.6 million, or $3.67 per diluted common share.

11 Feb 2010

AMA unhappy with Senate plan for Medicare 'doc fix'

The American Medical Association is criticizing "a Senate plan for avoiding a proposed 21 percent cut in government payments to physicians who treat the elderly, calling the proposal a 'Band-Aid' measure," Bloomberg/BusinessWeek reports.

11 Feb 2010

Cognitive behavioral therapy effective for insomnia and chronic pain

Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.

11 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

Study suggests obesity prevention efforts should begin much earlier

While many adults consider a chubby baby healthy, too many plump infants grow up to be obese teens, saddling them with Type-2 diabetes, elevated cholesterol and high blood pressure, according to an article published this month in the journal Clinical Pediatrics (published by SAGE).

11 Feb 2010

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

Nippon Product Acquisition commences tender offer to acquire outstanding shares of Home Diagnostics

Nipro Corporation, through its wholly-owned subsidiary Nippon Product Acquisition Corporation (the “Purchaser”), today commenced a cash tender offer to purchase all outstanding shares of Home Diagnostics, Inc. pursuant to an Agreement and Plan of Merger among Nipro, the Purchaser and Home Diagnostics dated February 2, 2010 (the “Merger Agreement”).

11 Feb 2010

RadPharm and Medifacts International announce merger

RadPharm Inc., a leading Imaging Core Laboratory, and Medifacts International, Inc., a leading Cardiovascular Core Laboratory, today announced the merger of their business operations. The combined company will be named CoreLab Partners ("CoreLabs") and will have its corporate headquarters in Princeton, New Jersey.

11 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

IDEXX Laboratories' Board authorizes increase in share repurchase program

IDEXX Laboratories, Inc., announced today that its Board of Directors has authorized the repurchase by the Company of up to an additional four million shares of its common stock under its ongoing share repurchase program.

11 Feb 2010

Cambridge Heart submits 510(k) application for Microvolt T-wave Alternans OEM Module

Cambridge Heart, Inc., today announced that the Company has completed the development phase of its Microvolt T-wave Alternans (MTWA) OEM Module, and has submitted a 510(k) application for regulatory approval with the U.S. Food and Drug Administration (FDA). The module is the centerpiece of the Company’s new business model that involves partnering with leading stress test equipment manufacturers to broaden the distribution and use of MTWA technology.

11 Feb 2010

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for intravenous (IV) acetaminophen.

11 Feb 2010

Biodel's VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel

Biodel, Inc. announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company’s two Phase 3 studies with VIAject® ultra-rapid-acting recombinant human insulin in a platform presentation at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland, on Friday, February 12, 2010, at 1pm central European time.

11 Feb 2010

NovaMed reports total net revenue of $39.8M for fourth-quarter 2009

NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the fourth quarter and year ended December 31, 2009. Total net revenue grew to $39,809,000, up 10% from $36,177,000 in the prior year fourth quarter. Same-facility net revenue growth was 6% for the quarter.

11 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

LabCorp reports financial results for quarter and year ended December 31, 2009

Laboratory Corporation of America® Holdings (LabCorp®) today announced results for the quarter and year ended December 31, 2009.

11 Feb 2010

Medical News

FDA grants approval for Abbott's antiretroviral medication Norvir

Alcon reports 2009 fourth quarter results

Chemical compound found in blood shows promise in preventing intractable form of heart failure

APCapital announces net income of $9.7M for fourth-quarter of 2009

AMA unhappy with Senate plan for Medicare 'doc fix'

Cognitive behavioral therapy effective for insomnia and chronic pain

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

Study suggests obesity prevention efforts should begin much earlier

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Nippon Product Acquisition commences tender offer to acquire outstanding shares of Home Diagnostics

RadPharm and Medifacts International announce merger

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

IDEXX Laboratories' Board authorizes increase in share repurchase program

Cambridge Heart submits 510(k) application for Microvolt T-wave Alternans OEM Module

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Biodel's VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel

NovaMed reports total net revenue of $39.8M for fourth-quarter 2009

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

LabCorp reports financial results for quarter and year ended December 31, 2009

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News